Inogen revenue falls, but Q2 earnings beat analyst estimates
The COVID-19 pandemic continued to cut into Inogen’s revenue, as new physician referrals and patient mobility declined during a quarter usually marked by increased patient travel and demand. Revenue fell nearly 30 percent in the second quarter to $71.7 million, missing average analyst estimates, and net income of $2.7 million was down from $9.9 million Read More →
Amgen teams up with competitors in COVID treatment trial
Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →
Deckers beats expectations with rising sales, shrinking losses in second quarter
Goleta-based Deckers Brands, the parent company of Ugg and Teva, saw its net sales increase in the second quarter as the footwear company continued to beat expectations and trim expenses. Sales increased 2.3 percent, to $283.2 million, compared to $276.8 million at the same point in 2019. The company still took a loss, but the Read More →
LTC sees big revenue drop after rent losses
LTC Properties’ net income dropped more than 90 percent from the second quarter of 2019 to the second quarter of 2020, as the Westlake Village-based senior-housing property investment trust wrote off $17.7 million in rent. LTC’s stock dropped after the July 31 earnings announcement. It opened at $38.38 on Aug. 1 and was at $36.78 Read More →
Amgen meets analyst estimates, but shares drop on Q2 earnings decline
Amgen’s revenues climbed 6 percent in the second quarter, to $6.2 billion, despite the COVID-19 pandemic limiting hospital and physician operations and putting a hitch in diagnosis and treatment for many patients. Amgen’s earnings, announced July 28, met average analyst estimates. However, a 17 percent overall decline in net income for the Thousand Oaks biotech Read More →
Pandemic still top concern for Community West following Q2 earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.